These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
420 related articles for article (PubMed ID: 34479065)
1. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065 [TBL] [Abstract][Full Text] [Related]
2. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation. Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640 [TBL] [Abstract][Full Text] [Related]
3. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808 [TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme. El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967 [TBL] [Abstract][Full Text] [Related]
5. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3- Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Elwan A; Elkady H J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1093-1114. PubMed ID: 34056992 [TBL] [Abstract][Full Text] [Related]
6. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation. El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720 [TBL] [Abstract][Full Text] [Related]
7. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596 [TBL] [Abstract][Full Text] [Related]
8. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors. Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416 [TBL] [Abstract][Full Text] [Related]
9. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Alsaif NA; Mahdy HA; Alanazi MM; Obaidullah AJ; Alkahtani HM; Al-Hossaini AM; Al-Mehizi AA; Elwan A; Taghour MS Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100359. PubMed ID: 34862634 [TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors. El-Adl K; El-Helby AA; Sakr H; Elwan A Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. Abdallah AE; Mabrouk RR; Al Ward MMS; Eissa SI; Elkaeed EB; Mehany ABM; Abo-Saif MA; El-Feky OA; Alesawy MS; El-Zahabi MA J Enzyme Inhib Med Chem; 2022 Dec; 37(1):573-591. PubMed ID: 35012403 [TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors. El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374 [TBL] [Abstract][Full Text] [Related]
13. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study. El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114 [TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053 [TBL] [Abstract][Full Text] [Related]